Key facts
- RxWare’s last known valuation is $19.5M (Jan 2020).
- It has raised $13.8M across 2 recorded rounds; the latest was Early Stage VC ($6.1M) in Aug 2025.
- Notable investors include Adam Fine, Calin Fusu, Chris Bergstrom, ConnectiveRx, IBM Alpha Zone Accelerator — 18 tracked in total.
- RxWare has filed 3 Form Ds with the SEC since 2024, most recently Aug 2025 ($6.1M sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for RxWare
Funding rounds
2 roundsAbout RxWare
Developer of a digital platform designed for connecting patients with essential services. The company's platform is flexible, scalable and secure to enhance patient engagement throughout the entire specialty prescription journey, enabling pharmaceutical brands to improve patient lives.
- Sector
- Healthcare
- HQ
- Wilmington, DE, United States
- Founded
- 2013
- Employees
- 30
- Website
- rxware.io/
- Ownership
- Privately Held (backing)
RxWare doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RxWare shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RxWare in its N-PORT filings yet. We sweep new filings monthly.